Adamantane-resistant influenza infection during the 2004-05 season

Emerging Infectious Diseases

Volumn 14, Issue 1, 2008, Pages 173-176

  Rahman, Mahbubur ^a,c   Bright, Rick A ^b,d   Kieke, Burney A ^a   Donahue, James G ^a   Greenlee, Robert T ^a   Vandermause, Mary ^a   Balish, Amanda ^b   Foust, Angela ^b   Cox, Nancy J ^b   Klimov, Alexander I ^b   Shay, David K ^b   Belongia, Edward A ^a  

^a MARSHFIELD CLINIC   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d NOVAVAX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; DISEASE DURATION; FEMALE; HIGH RISK PATIENT; HUMAN; INFANT; INFLUENZA; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POINT MUTATION; PREVALENCE; SYMPTOM; UNITED STATES; VIRUS ISOLATION;

EID: 38049035374     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1401.070460     Document Type: Article

References (16)

1. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580-4.
2. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am. 1987;1:459-78.
3. Younkin SW, Betts RF, Roth FK, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983;23:577-82.
4. Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989;11:27-40.
5. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993;67:5585-94.
6. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175-81.
7. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891-4.
8. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis. 1991;164:969-72.
9. Abed Y, Goyette N, Bolvin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother. 2005;49:556-9.
10. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696-702.
11. Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med. 1992;152:390-2.
12. Mast EE, Harmon MW, Gravenstein S, Wu SP, Arden NH, Circo R, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol. 1991;134:988-97.
13. Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000;284:1677-82.
14. Nelson MI, Simonsen L, Viboud C, Miller MA, Taylor J, George KS, et al. Stochastic processes are key determinants of short-term evolution in influenza A virus. PLoS Pathogens. 2006;2:e125.
15. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-42.
16. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.